Omeros Corporation
Seattle, WA
- UEI
- HM97JEC22LP2
- CAGE
- 357C4
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Waterfront Research Center, 201 Elliott Ave W, Seattle, WA 98119, USA
- Website
- omeros.com
- Founded
- 1994
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| U.s. Division | Rockville, MD | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Arrowhead Pharmaceuticals, Inc. | Pasadena, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Botanix SB Inc. | Phoenix, AZ | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Purdue Pharma LIMITED Partnership | Stamford, CT | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Omeros Corporation, a for-profit pharmaceutical manufacturer, holds federal supply schedule contracts and a cooperative agreement as a prime recipient, operating in the pharmaceuticals and drugs market with no subcontracting footprint across recent federal work.
Omeros is a corporate entity headquartered in the pharmaceutical sector, competing under full-and-open (non-set-aside) contract vehicles. The vendor operates primarily under NAICS Pharmaceutical Preparation Manufacturing, with PSC coding aligned to Drugs and Biologicals. Recent activity spans two distinct customer bases: the Department of Veterans Affairs accounts for five awards totaling $19.7 million in combined potential value, while the Department of Health and Human Services National Institutes of Health accounts for eight awards (one routed through the National Institute on Drug Abuse). The veteran's affairs dollars sit almost entirely on GSA Federal Supply Schedule contracts under the Pharmaceuticals and Drugs schedule (FSS-61-IB), where Omeros holds two active positions: a multiple-award FSS contract awarded September 1, 2026, with a $475,000 ceiling extending through August 31, 2031, and an interim FSS agreement from March 4, 2026, carrying a $25,000 ceiling through August 31, 2026. Both contracts operate nationwide and enable VA and other federal agencies to place orders directly against Omeros's price list without separate competition.
On the NIH side, Omeros is a federal grant recipient on a $19.7 million cooperative agreement from the National Institute on Drug Abuse awarded April 15, 2023, and scheduled for completion March 31, 2027. This grant funds preclinical toxicology studies and a clinical trial for OMS182399, a phosphodiesterase 7 (PDE7) inhibitor candidate designed to treat cocaine use disorder by restoring dopamine regulation in persons with substance use disorder. The grant requires completion of IND-enabling studies and a phase 1 clinical safety and preliminary efficacy study in persons with cocaine use disorder.
Award velocity is sparse — one award in 2021, one in 2023, two in 2026 — with one award (the interim FSS contract) reaching completion inside the next twenty-four months. Combined potential value across all fourteen awards stands at $19.7 million, with obligated dollars exceeding potential value at $21.2 million, indicating invoiced work running above contract ceiling. Omeros operates as a 100% prime across recent federal work with no documented subcontracting activity.
Quick answers
Is Omeros Corporation registered in SAM.gov?
Yes. Omeros Corporation's SAM.gov registration is active through November 2, 2027.
What is Omeros Corporation's CAGE code?
Omeros Corporation's CAGE code is 357C4, and its Unique Entity ID (UEI) is HM97JEC22LP2.
Which contract vehicles does Omeros Corporation hold?
Omeros Corporation holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Omeros Corporation's most recent federal award?
Omeros Corporation's most recent federal grant award is PDE7 inhibitor for the treatment of cocaine use disorder (U01DA058541), from National Institute on Drug Abuse (NIH), on April 15, 2023.
On GovTribe
See Omeros Corporation's full federal record
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors